SIR1-365 is an oral small-molecule RIPK1 kinase inhibitor with anti-inflammatory and immunomodulatory activity.
Nov 27 2021 |
et al., NCT04622332 | A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19 |
| 88% worse recovery (p=0.44). Pilot RCT 42 hospitalized COVID-19 patients showing no significant differences with SIR1-365 treatment. foo | ||